The MarketWatch News Department was not involved in the creation of this content. HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of ...

HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, announces that its Chief ...

The Company’s Initial Addressable Market Includes Approximately 2.5 Million Peripheral Endovascular Procedures in the U.S. Annually CEO, President & Chairman to Present Live Webcast at the H.C.

Limited Market Release (LMR) of the LIBERTY ® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 ...

HINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of ...

Microbot Medical has secured a non-dilutive NIS2.15m (around $630,000) grant from the Israel Innovation Authority (IIA) to bolster its manufacturing capabilities, as well as progress towards the ...

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries ...

Microbot Medical Inc. MBOT recently received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a major regulatory milestone for the company. The LIBERTY system is designed to ...

HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, today announced that Harel Gadot, ...